ATF6 Modulating Compounds for Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for diseases mediated by Activating Transcription Factor 6 (ATF6) lack effective modulators to precisely control ATF6 signaling, which is crucial for managing various pathological conditions such as cancer, neurodegenerative diseases, and vascular disorders, as existing treatments often have limited efficacy and resistance issues.
Innovation Solution
Development of specific compounds, represented by formulas (I-1) and (I-2), which can modulate ATF6 activity by administering them to individuals in need, thereby treating diseases characterized by ATF6 activation, including cancer, neurodegenerative disorders, and vascular diseases, with the potential to combine with other agents to enhance therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic strategies are used for diseases mediated by ATF6, then treatment is provided, but efficacy is limited and resistance issues occur
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formulas I-1 and I-2) that modify the biochemical parameters of ATF6 signaling. These compounds change the activation state, duration, and intensity of ATF6-mediated transcriptional responses, thereby overcoming treatment resistance and improving efficacy in diseases such as cancer, neurodegenerative disorders, and vascular diseases
2Reliability
If ATF6 signaling is modulated to treat diseases, then therapeutic outcomes improve, but precise control of ATF6 signaling is currently lacking
Solution Approach 1:
The patent implements feedback control mechanisms through compounds that respond to and modulate ATF6 signaling states. The compounds are designed to provide controlled activation or inhibition of ATF6 pathways, enabling precise regulation of the transcriptional response based on disease state requirements, thereby achieving reliable therapeutic outcomes with precise signaling control
Data Source
AI summary
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))